Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis

Oral mucositis patient provider advisory board

Lisa A. Bellm, Gail Cunningham, Laurie Durnell, June G Eilers, Joel B. Epstein, Tom Fleming, Henry J. Fuchs, Martha Nash Haskins, Mary M. Horowitz, Paul J. Martin, Deborah B. McGuire, Kevin Mullane, Gerry Oster

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Oral mucositis (OM)-related outcomes constituting a meaningful clinical advance in bone marrow transplant patients were considered by an interdisciplinary panel. Meaningful outcomes are essential in product development for OM, a condition without effective prevention or treatment. The most important outcomes to measure, the feasibility of measuring these in a clinical trial, and clinically meaningful differences in these outcomes were determined by the panel. Most important are reduction in oral pain and use of opioid analgesics, improvement in oral intake and quality of life, and reduction of hospitalization duration. Reduction in the severity of OM measured by an objective evaluation of oral mucosa could provide insight regarding the biologic activity of an intervention. Further data are required to define the precise relationship between reduction in visible OM and improvement in outcome. Minimally, clinical trials for OM should assess oral pain, opioid use, oral intake, and include objective assessment of OM.

Original languageEnglish (US)
Pages (from-to)793-800
Number of pages8
JournalCancer Investigation
Volume20
Issue number5-6
DOIs
StatePublished - Dec 1 2002

Fingerprint

Stomatitis
Opioid Analgesics
Therapeutics
Clinical Trials
Pain
Mouth Mucosa
Hospitalization
Bone Marrow
Quality of Life
Outcome Assessment (Health Care)
Transplants

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis : Oral mucositis patient provider advisory board. / Bellm, Lisa A.; Cunningham, Gail; Durnell, Laurie; Eilers, June G; Epstein, Joel B.; Fleming, Tom; Fuchs, Henry J.; Haskins, Martha Nash; Horowitz, Mary M.; Martin, Paul J.; McGuire, Deborah B.; Mullane, Kevin; Oster, Gerry.

In: Cancer Investigation, Vol. 20, No. 5-6, 01.12.2002, p. 793-800.

Research output: Contribution to journalArticle

Bellm, LA, Cunningham, G, Durnell, L, Eilers, JG, Epstein, JB, Fleming, T, Fuchs, HJ, Haskins, MN, Horowitz, MM, Martin, PJ, McGuire, DB, Mullane, K & Oster, G 2002, 'Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board', Cancer Investigation, vol. 20, no. 5-6, pp. 793-800. https://doi.org/10.1081/CNV-120002497
Bellm, Lisa A. ; Cunningham, Gail ; Durnell, Laurie ; Eilers, June G ; Epstein, Joel B. ; Fleming, Tom ; Fuchs, Henry J. ; Haskins, Martha Nash ; Horowitz, Mary M. ; Martin, Paul J. ; McGuire, Deborah B. ; Mullane, Kevin ; Oster, Gerry. / Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis : Oral mucositis patient provider advisory board. In: Cancer Investigation. 2002 ; Vol. 20, No. 5-6. pp. 793-800.
@article{231dcd6f21da4fba8f3a11aa4d4ca591,
title = "Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board",
abstract = "Oral mucositis (OM)-related outcomes constituting a meaningful clinical advance in bone marrow transplant patients were considered by an interdisciplinary panel. Meaningful outcomes are essential in product development for OM, a condition without effective prevention or treatment. The most important outcomes to measure, the feasibility of measuring these in a clinical trial, and clinically meaningful differences in these outcomes were determined by the panel. Most important are reduction in oral pain and use of opioid analgesics, improvement in oral intake and quality of life, and reduction of hospitalization duration. Reduction in the severity of OM measured by an objective evaluation of oral mucosa could provide insight regarding the biologic activity of an intervention. Further data are required to define the precise relationship between reduction in visible OM and improvement in outcome. Minimally, clinical trials for OM should assess oral pain, opioid use, oral intake, and include objective assessment of OM.",
author = "Bellm, {Lisa A.} and Gail Cunningham and Laurie Durnell and Eilers, {June G} and Epstein, {Joel B.} and Tom Fleming and Fuchs, {Henry J.} and Haskins, {Martha Nash} and Horowitz, {Mary M.} and Martin, {Paul J.} and McGuire, {Deborah B.} and Kevin Mullane and Gerry Oster",
year = "2002",
month = "12",
day = "1",
doi = "10.1081/CNV-120002497",
language = "English (US)",
volume = "20",
pages = "793--800",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis

T2 - Oral mucositis patient provider advisory board

AU - Bellm, Lisa A.

AU - Cunningham, Gail

AU - Durnell, Laurie

AU - Eilers, June G

AU - Epstein, Joel B.

AU - Fleming, Tom

AU - Fuchs, Henry J.

AU - Haskins, Martha Nash

AU - Horowitz, Mary M.

AU - Martin, Paul J.

AU - McGuire, Deborah B.

AU - Mullane, Kevin

AU - Oster, Gerry

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Oral mucositis (OM)-related outcomes constituting a meaningful clinical advance in bone marrow transplant patients were considered by an interdisciplinary panel. Meaningful outcomes are essential in product development for OM, a condition without effective prevention or treatment. The most important outcomes to measure, the feasibility of measuring these in a clinical trial, and clinically meaningful differences in these outcomes were determined by the panel. Most important are reduction in oral pain and use of opioid analgesics, improvement in oral intake and quality of life, and reduction of hospitalization duration. Reduction in the severity of OM measured by an objective evaluation of oral mucosa could provide insight regarding the biologic activity of an intervention. Further data are required to define the precise relationship between reduction in visible OM and improvement in outcome. Minimally, clinical trials for OM should assess oral pain, opioid use, oral intake, and include objective assessment of OM.

AB - Oral mucositis (OM)-related outcomes constituting a meaningful clinical advance in bone marrow transplant patients were considered by an interdisciplinary panel. Meaningful outcomes are essential in product development for OM, a condition without effective prevention or treatment. The most important outcomes to measure, the feasibility of measuring these in a clinical trial, and clinically meaningful differences in these outcomes were determined by the panel. Most important are reduction in oral pain and use of opioid analgesics, improvement in oral intake and quality of life, and reduction of hospitalization duration. Reduction in the severity of OM measured by an objective evaluation of oral mucosa could provide insight regarding the biologic activity of an intervention. Further data are required to define the precise relationship between reduction in visible OM and improvement in outcome. Minimally, clinical trials for OM should assess oral pain, opioid use, oral intake, and include objective assessment of OM.

UR - http://www.scopus.com/inward/record.url?scp=0036044122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036044122&partnerID=8YFLogxK

U2 - 10.1081/CNV-120002497

DO - 10.1081/CNV-120002497

M3 - Article

VL - 20

SP - 793

EP - 800

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5-6

ER -